Log In
BCIQ
Print this Print this
 

JDE-003

  Manage Alerts
Collapse Summary General Information
Company EyeGate Pharmaceuticals Inc.
Description0.75% cross-linked eye drop formulation of thiolated carboxymethyl hyaluronic acid (CMHA-S)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentIND
Standard IndicationCorneal wound
Indication DetailsTreat corneal wound
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$5.4M

0

$2.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/07/2016

$5.4M

0

$2.2M

Get a free BioCentury trial today